Onderneming TransCode Therapeutics, Inc.
Aandelen
RNAZ
US89357L3033
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,823 USD | +16,41% | +49,85% | -87,50% |
Vakgebied
Aantal werknemers: 10
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 73 | 01-07-18 | |
Zdravka Medarova
FOU | Founder | 50 | 01-01-16 |
Susan Duggan
COO | Chief Operating Officer | - | - |
Alan Freidman
IRC | Investor Relations Contact | - | - |
Seth Gregg
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Magda Marquet
BRD | Director/Board Member | 65 | 01-01-21 |
Philippe Calais
CHM | Chairman | 65 | 01-10-18 |
Erik Manting
BRD | Director/Board Member | 53 | 20-12-20 |
Chief Executive Officer | 73 | 01-07-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 6 108 053 | 5 799 563 ( 94,95 %) | 0 | 94,95 % |
Bedrijfsgegevens
TransCode Therapeutics, Inc.
6 Liberty Square Suite 2382
02109, Boston
+
http://www.transcodetherapeutics.comSector
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-87,50% | 4,32 mln. | |
-1,64% | 103 mld. | |
+7,50% | 101 mld. | |
+4,40% | 23,07 mld. | |
-12,18% | 22,23 mld. | |
-4,36% | 18,05 mld. | |
-39,98% | 17,18 mld. | |
-10,70% | 16,94 mld. | |
+6,94% | 14,07 mld. | |
+38,02% | 12,35 mld. |
- Beurs
- Aandelen
- Koers RNAZ
- Onderneming TransCode Therapeutics, Inc.